ONCO — Oncopeptides AB Share News
0.000.00%
Last trade - 00:00- SEK665.09m
- SEK642.65m
- SEK71.12m
Brief: European Commission Approves Oncopeptides' Pepaxti
Brief: Oncopeptides Q2 Net Loss Widens To SEK 59.8 Million
Brief: Oncopeptides: FDA ODAC To Discuss Benefit/Risk Profile Of Pepaxto In September
Brief: Oncopeptides Says Has Carried Out A Directed Share Issue Of About SEK 435.6 Mln
Brief: Oncopeptides Says CHMP Issues A Positive Opinion Recommending Full Approval Of Oncopeptides Pepaxti In EU For Patients With Triple Class Refractory Multiple Myeloma
Brief: Oncopeptides Q1 Operating Loss Narrows To SEK 98.9 Mln
Brief: Oncopeptides Q4 Net Loss Narrows To Sek 394.0 Mln
Brief: Oncopeptides Says Rescinds Voluntary Withdrawal Of Pepaxto In The U.S.
Brief: Oncopeptides Announces Year-End Cash 2021
Brief: Oncopeptides Presents New Melflufen Data At Annual American Society Of Hematology Meeting ASH
Brief: Oncopeptides Q3 Operating Loss Narrows To SEK 338.9 Mln
Brief: Jakob Lindberg Is Appointed CEO Of Oncopeptides
Oncopeptides plummets on Pepaxto withdrawal in U.S., scale down plan
Brief: Oncopeptides Withdraws Pepaxto In US
Brief: Oncopeptides' Says CFO Anders Martin-Löf Will Leave Co
Brief: Magle Chemoswed Establishes Agreement With Oncopeptides
Brief: Oncopeptides Presents Phase 3 Ocean Study Results At IMW Meeting
Brief: Oncopeptides Q2 Operating Loss Narrows To SEK 344.8 Mln
Brief: Oncopeptides: Regulatory Update From Us Food And Drug Administration